Eli L Diamond1, Katherine S Panageas2, Alexis Dallara3, Ariel Pollock4, Allison J Applebaum5, Alan C Carver6, Elena Pentsova7, Lisa M DeAngelis7, Holly G Prigerson8. 1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Palliative Medicine Service, Division of Survivorship and Supportive Care, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York, USA. Electronic address: diamone1@mskcc.org. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Department of Neurology, Columbia University Medical Center, New York, New York, USA. 4. Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, USA. 5. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Palliative Medicine Service, Division of Survivorship and Supportive Care, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 7. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 8. Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York, USA.
Abstract
CONTEXT: Glioblastoma (GBM) is a devastating and incurable neuro-oncologic disease, and issues related to the end of life are almost invariably a matter of "when," not a matter of "if." Optimizing symptom management and quality of life in later stages of disease is of the utmost priority. OBJECTIVES: To examine the frequency of and factors associated with late acute hospital admission before death in patients with GBM. METHODS: Case-control study comparing patients with GBM admitted to the hospital within one month of death to those without late hospital admission. RESULTS: Of 385 GBM patients followed to death at Memorial Sloan Kettering Cancer Center, 164 (42.6%) were admitted within a month of death, most frequently (140, or 85%) to manage neurologic decline. Of these, 56 (34%) had intensive care unit care during this admission and 22 (13%), 18 (11%), and 2 (1%) received mechanical ventilation, enteral feeding tubes, or cardiopulmonary resuscitation, respectively. In multivariable analysis, in-hospital chaplaincy consultation, and participation in a therapeutic clinical trial, both at any time in the GBM disease course, were significantly associated with late hospital admission. CONCLUSIONS: Late hospitalization is frequent in GBM and often involves intensive care unit care in the management of clinical events that are part of the GBM dying process. Patients with a tendency to use religious support and those enrolled in clinical trials may be at greater risk for late hospitalization. Dedicated prospective study is needed to determine predictors of late hospitalization and to examine the impact of late acute medical care on quality of life in GBM.
CONTEXT: Glioblastoma (GBM) is a devastating and incurable neuro-oncologic disease, and issues related to the end of life are almost invariably a matter of "when," not a matter of "if." Optimizing symptom management and quality of life in later stages of disease is of the utmost priority. OBJECTIVES: To examine the frequency of and factors associated with late acute hospital admission before death in patients with GBM. METHODS: Case-control study comparing patients with GBM admitted to the hospital within one month of death to those without late hospital admission. RESULTS: Of 385 GBM patients followed to death at Memorial Sloan Kettering Cancer Center, 164 (42.6%) were admitted within a month of death, most frequently (140, or 85%) to manage neurologic decline. Of these, 56 (34%) had intensive care unit care during this admission and 22 (13%), 18 (11%), and 2 (1%) received mechanical ventilation, enteral feeding tubes, or cardiopulmonary resuscitation, respectively. In multivariable analysis, in-hospital chaplaincy consultation, and participation in a therapeutic clinical trial, both at any time in the GBM disease course, were significantly associated with late hospital admission. CONCLUSIONS: Late hospitalization is frequent in GBM and often involves intensive care unit care in the management of clinical events that are part of the GBM dying process. Patients with a tendency to use religious support and those enrolled in clinical trials may be at greater risk for late hospitalization. Dedicated prospective study is needed to determine predictors of late hospitalization and to examine the impact of late acute medical care on quality of life in GBM.
Authors: J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld Journal: J Neurooncol Date: 2014-08-24 Impact factor: 4.130
Authors: Adam Bostanci; Dell Horey; Kate Jackson; Leeroy William; Lise Pittmann; Jennifer Ward; Gaye Moore; Peter Martin; Peter Hudson; Jennifer Philip Journal: Eur J Cancer Care (Engl) Date: 2015-04-22 Impact factor: 2.520
Authors: Vijaya Sundararajan; Megan A Bohensky; Gaye Moore; Caroline A Brand; Carrie Lethborg; Michelle Gold; Michael A Murphy; Anna Collins; Jennifer Philip Journal: J Neurooncol Date: 2014-01 Impact factor: 4.130
Authors: Wendy G Lichtenthal; Matthew Nilsson; Baohui Zhang; Elizabeth D Trice; David W Kissane; William Breitbart; Holly G Prigerson Journal: Psychooncology Date: 2009-01 Impact factor: 3.894
Authors: Laura L Dover; Caleb R Dulaney; John B Fiveash; Courtney P Williams; Bradford E Jackson; Paula Warren; Gabrielle B Rocque Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: A J Applebaum; K Buda; M Kryza-Lacombe; J J Buthorn; R Walker; K M Shaffer; T A D'Agostino; E L Diamond Journal: Psychooncology Date: 2017-12-19 Impact factor: 3.894
Authors: Ugur Sener; Elizabeth C Neil; Amy Scharf; Alan C Carver; Justin B Buthorn; Dana Bossert; Allison M Sigler; Louis P Voigt; Eli L Diamond Journal: Neurooncol Pract Date: 2021-06-19
Authors: Eli L Diamond; Holly G Prigerson; Denise C Correa; Anne Reiner; Katherine Panageas; Maria Kryza-Lacombe; Justin Buthorn; Elizabeth C Neil; Alex M Miller; Lisa M DeAngelis; Allison J Applebaum Journal: Neuro Oncol Date: 2017-10-19 Impact factor: 12.300
Authors: Marissa Barbaro; Craig D Blinderman; Fabio M Iwamoto; Teri N Kreisl; Mary R Welch; Yazmin Odia; Laura E Donovan; Adela E Joanta-Gomez; Katharine A Evans; Andrew B Lassman Journal: Neurology Date: 2021-11-18 Impact factor: 9.910
Authors: Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton Journal: J Pain Symptom Manage Date: 2019-10-19 Impact factor: 3.612